OBJECTIVES: Chronic hepatitis C virus (HCV) is a considerable public health concern due to its significant impact on morbidity, mortality and healthcare costs. Treatment of HCV genotype 1 (GT1)-infected patients with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin (OBV/PTV/r/DSV±R) demonstrated significantly high sustained viral response (SVR) rates and negligible adverse events in clinical studies. This study evaluated the cost per SVR for OBV/PTV/r/DSV±R compared to sofosbuvir in combination with daclatasvir (SOF+DCV) or simeprevir (SOF+SIM) in HCV treatment-naïve patients with GT1 for The Netherlands. METHODS: An economic evaluation comparing OBV/PTV/r/DSV±R to SOF+DCV or SOF+SIM in terms of costs per SVR was performed from the Dutch societal perspective. A Markov model with a lifetime time horizon was developed based on previous published models in HCV. Transition probabilities, resource use and costs for reference year 2014 were derived from the literature, publically available sources and expert opinion. SVR rates for all therapies were derived from published literature. Baseline characteristics (e.g., age, fibrosis distribution) were based on the OBV/PTV/r/DSV±R trials. RESULTS: In treatment-naïve HCV GT1 patients, the overall trial SVR rate for OBV/PTV/r/DSV±R was 97% (688/708), 98% (124/126) for SOF+DCV and 89% (17/19) for SOF+SIM. Total costs were lower for OBV/PTV/r/DSV±R (€55,864) compared to SOF+DCV (€83,679) and SOF+SIM (€81,746). Total costs per SVR were also lower for OBV/PTV/r/DSV±R (€57,592) compared to SOF+DCV (€85,387) and SOF+SIM (€91,849). Treatment with OBV/PTV/r/DSV±R resulted in a cost-savings of €27,795 and €34,257 per responding patient compared to SOF+DCV and SOF+SIM, respectively. CONCLUSIONS: Total costs per successfully treated treatment-naïve HCV GT1 patient with OBV/PTV/r/DSV±R are lower compared to sofosbuvir in combination daclatasvir or simeprevir for the Dutch society. Treatment with OBV/PTV/r/DSV±R would lead to cost-savings and thus improve the overall budget impact of HCV in the Netherlands.